Skip to main content
Premium Trial:

Request an Annual Quote

Transplant Genomics Grants Four Institutes Early Access to Kidney Transplant Test

This article has been updated to correct an explanation of how the test works versus the current standard of care.

NEW YORK (GenomeWeb) – Molecular diagnostics firm Transplant Genomics today announced that its TruGraf post-kidney transplant blood tests have been accepted for use by four transplant centers under an early-access program — California Pacific Medical Center, the Henry Ford Health System, Houston Methodist Hospital, and the University of Wisconsin.

"Our early access partners are the first clinicians to use TruGraf in a clinical environment," Transplant Genomics CMO Roy First said in a statement. "We're thrilled to be working with these centers that will have the opportunity to use the TruGraf blood test to support decisions regarding immunosuppressive management of kidney transplant patients."

Under the early-access program, the participating institutions will receive access to the TruGraf test, as well as high-level logistical support. Additional terms were not disclosed.

According to Transplant Genomics, the TruGraf technology analyzes gene expression profiles to detect molecular signatures of acute transplant rejection, enabling differentiation of this clinical phenotype from other non-immune causes of dysfunction in kidney transplant patients. The firm believes its test offers several advantages over the current method for monitoring kidney graft recipients, which involves measuring serum creatinine levels.

Transplant Genomics is also developing tests to diagnose subclinical episodes of transplant rejection. It expects the new diagnostics to be available through the early-access program in the coming months.